Clinical Trials
41
8 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1845
Active, not recruiting
3
7.3%
Completed
27
65.8%
Not yet recruiting
5
12.2%
Recruiting
5
12.2%
Unknown
1
2.4%
No approval data available
- University of Colorado Boulder researchers discovered that para-tyramine-O-sulfate (pTOS), a metabolite found in python blood, acts as an appetite suppressant in mice without causing gastrointestinal problems or muscle loss. - The compound increases 1,000-fold in pythons after feeding and targets the brain's hunger center, leading to weight loss in both obese and lean mice when administered at high doses. - Scientists have formed Arkana Therapeutics to develop synthetic versions of pTOS and other python metabolites into commercial weight loss drugs that could avoid common side effects of current GLP-1 medications. - The research represents a nature-inspired approach to drug development, leveraging pythons' extraordinary ability to survive extreme feeding cycles without metabolic damage.
- Breakthru Medicine has completed a $60 million Series A financing round to develop disruptive therapeutic modalities for cancer patients with major unmet medical needs. - The company was founded by biotech veterans with experience in over a dozen approved or late-stage therapies, most receiving FDA Breakthrough Therapy Designation. - Breakthru's platform combines small molecules, next-generation ADC payloads, and molecular glues to target previously undruggable cancer targets. - The company employs a patient-first, tumor-agnostic targeting approach focusing on therapy areas where existing treatments have shown limited success.
- A novel patient navigation intervention (NDURE) doubled the rate of timely post-operative radiation therapy initiation in head and neck cancer patients, showing a 35% improvement over usual care. - The intervention successfully reduced racial disparities in treatment delays between Black and white patients, demonstrating potential for improving healthcare equity. - The scalable program, being validated in a multi-center trial across four major institutions, focuses on patient education, social risk screening, and improved care coordination.
